Skip to main content
OpenTrials
Completed

NCT Number: NCT02520232

Pathological and Non-pathological Aging, Physical Activity, Genotype and Cognition

Alzheimer's disease (AD) is an irreversible, progressive brain disease. It is the most common form of dementia and the major cause of functional dependence in the elderly. Since there is currently no cure for Alzheimer's disease, a growing number of scientists pointed out the interest to use non-pharmacological alternative therapeutic approaches in order to slow down the decline of physical and cognitive resources and improve quality of life of patients with Alzheimer's disease. Several narrative and meta-analytical reviews suggest that regular practice of physical activity delays the occurrence of cognitive decline and slows down Alzheimer's disease progress when compared with sedentary people. Despite the growing interest of the scientific community for the positive effects of chronic exercise on mental health and cognitive functions, the clinical reality of this phenomenon remains to be clearly established, more particularly in aged people suffering from neurodegenerative diseases.The first aim of this research project is to test if chronic exercise reduces and even compensates for a cognitive decline in both patients with prodromal Alzheimer's disease (i.e., no dementia) and aging people with no pathology of central nervous system. The second aim of this research project is to examine whether an increasing of cerebral blood flow induced by chronic exercise can explain this positive effect.

Completed

Looking for future studies?

Notify Me

Key information

Age range

60 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Bordeaux, France, Bordeaux, France

Loading trial locations.

About this study

Several epidemiologic studies conducted in North America and in Europe have shown that the regular practice of physical activity, in opposition to a sedentary life, is associated with a reduced risk of developing neurodegenerative diseases such as AD. These results have been strengthened by cross-sectional and interventional studies, which have shown that physical activity slows down the decline of cognitive functions typically observed in normal and pathological aging and retards the onset of dementia. The positive effects of chronic exercise on cerebral and cognitive ageing are now recognised by scientists and clinicians; however, the mechanisms underlying these effects in humans are poorly understood and there is a real need for randomised controlled trial (RCT) on this topic. The objective of this research project is to understand the compensatory mechanisms that may account for the positive effects of regular physical activity on pathological and non-pathological cerebral ageing in human and in particular in people presenting prodromal AD. All participants will be separated into six groups corresponding to the combination of two independent variables: the population type (aged people without any neurological disease vs. prodromal Alzheimer's disease participants) and the type of physical activity program they will follow during six months (aerobic and strength exercise program, stretching and balance program, or maintaining sedentary life style). Cognitive performance, cardiovascular health, brain integrity and cerebral functioning will be assessed at two or three different times: before the onset of the training program (pre-test), at the end of the training period (post-test 1) and six months after the end of the training program (post-test 2).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged between 60 and 80 years
  • Retired
  • Complete autonomy on the following four instrumental activities of daily living scales (IADL) : ability to use telephone, mode of transportation, responsibility for own medications and ability to handle finances, level of physical activity practice ≤ 2
  • 18.5 ≤ BMI < 40
  • MMSE ≥ 25
  • For prodromal Alzheimer Disease patients : subjective memory complaints of the participant, objective evidence of impaired encoding in episodic memory (Grober-Buschke free recall score < 17).

Exclusion criteria

  • Presence of a counter-indication for Magnetic Resonance Imaging , presence of a counter-indication for Positron Emission TomographyScan with [18F]-Flutemetamol, presence of any health problem preventing travel to the imaging service of the University Hospital, being under the legal guardianship of another person or being unable to provide consent to participate

Treatment and study plan

Combination of aerobic and strength exercises

Behavioral

Combination of aerobic and strength exercises

Stretching and balance exercise program

Behavioral

Stretching and balance exercise program

Primary outcomes

  1. Executive functions (Mean z score)

    Time frame: 0 to 3 months after inclusion visit

    Mean z score of performances in five tasks involving executive functions (Trail Making Test, Random Number Generation Task, Stroop Color Word Test, Eriksen's Flanker Task, Letter Running Span Task).

  2. Executive functions (Mean z score)

    Time frame: 6 to 9 months after inclusion visit

  3. Executive functions (Mean z score)

    Time frame: 12 to 15 months after inclusion visit

Secondary outcomes

  1. Senior Fitness Test score

    Time frame: 0 to 3 months after inclusion visit ; 6 to 9 months after inclusion visit ; 12 to 15 months after inclusion visit

  2. Body Mass Index

    Time frame: Day 0 (Inclusion visit)

  3. Energy expenditure related to physical activity (Actimetry)

    Time frame: 3 to 6 months after inclusion visit

    Actimetry meseare

  4. Heart rate variability at rest

    Time frame: 0 to 3 months after inclusion visit ; 6 to 9 months after inclusion visit ; 12 to 15 months after inclusion visit

  5. Blood pressure

    Time frame: 0 to 3 months after inclusion visit ; 6 to 9 months after inclusion visit ; 12 to 15 months after inclusion visit

  6. Depression score

    Time frame: 0 to 3 months after inclusion visit ; 6 to 9 months after inclusion visit ; 12 to 15 months after inclusion visit

  7. Self-efficacy score

    Time frame: 0 to 3 months after inclusion visit ; 6 to 9 months after inclusion visit ; 12 to 15 months after inclusion visit

  8. Quality of life score

    Time frame: 0 to 3 months after inclusion visit ; 6 to 9 months after inclusion visit ; 12 to 15 months after inclusion visit

  9. Stage of change score related to physical activity

    Time frame: 0 to 3 months after inclusion visit ; 6 to 9 months after inclusion visit ; 12 to 15 months after inclusion visit

  10. Score at Verbal working-memory span

    Time frame: 0 to 3 months after inclusion visit ; 6 to 9 months after inclusion visit ; 12 to 15 months after inclusion visit

  11. Reaction time in a two-choice reaction time task

    Time frame: 0 to 3 months after inclusion visit ; 6 to 9 months after inclusion visit ; 12 to 15 months after inclusion visit

  12. Error rate in a two-choice reaction time task

    Time frame: 0 to 3 months after inclusion visit ; 6 to 9 months after inclusion visit ; 12 to 15 months after inclusion visit

  13. Logic memory score

    Time frame: 0 to 3 months after inclusion visit ; 6 to 9 months after inclusion visit ; 12 to 15 months after inclusion visit

  14. Grey and white matter volumes in regions of interest

    Time frame: 0 to 3 months after inclusion visit ; 6 to 9 months after inclusion visit

  15. Cerebral perfusion in the same regions of interest

    Time frame: 0 to 3 months after inclusion visit ; 0 to 15 days after inclusion visit ; 6 to 9 months after inclusion visit

    Brain Imaging

  16. Resting State Networks Activity

    Time frame: 0 to 3 months after inclusion visit ; 0 to 15 days after inclusion visit ; 6 to 9 months after inclusion visit

    Brain Imaging

  17. Brain glucose metabolism

    Time frame: 0 to 3 months after inclusion visit ; 0 to 15 days after inclusion visit ; 6 to 9 months after inclusion visit

    Brain Imaging

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Collaborators

  • Centre National de la Recherche Scientifique, France
  • Poitiers University Hospital
  • University of Bordeaux
  • University of Poitiers

Registry information

Official study title

Pathological and Non-pathological Aging, Physical Activity, Genotype and Cognition (VIAGECO)

Acronym: VIAGECO

Important dates

Study start
2015
Primary completion
2017
Study completion
2018
First posted
Aug 11, 2015
Registry last updated
Jun 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.